DIAGNOSTIC IMAGING MODALITIES FOR DETECTION OF LUNG METASTASES IN PATIENTS WITH DIFFRENTIATED THYROID CANCER
Abstract
The aim of the study was to comparatively assess the efficacy of various diagnostic imaging modalities in detection of lung metastases of differentiated thyroid cancer. A retrospective analysis of the results of examination of 36 patients was carried out. Positron emission tomography/computed tomography (PET/ CT) with [F-18] fluorodeoxyglucose (FDG) was found to have the highest sensitivity for detection of lung metastases of differentiated thyroid cancer (100 %) followed by CT of the chest (95.5 %) and whole body scintigraphy (WBS) with 131I (66.7 %).
About the Authors
Т. М. Geliashvili
Chelyabinsk Regional Oncology Center, Chelyabinsk
Russian Federation
Russian Federation
Geliashvili Tamara Mamukovna, MD, radiologist, Radiation Therapy Department.
E-mail: geliashvili_tata@mail.ru.
A. V. Vazhenin
Chelyabinsk Regional Oncology Center, Chelyabinsk
Russian Federation
Russian Federation
Vazhenin Andrey Vladimirovich, MD, Professor, Corresponding Member of RAS, Honored physician of RF, Head of Department of Oncology, Radiation Therapy and Diagnostic Imaging, South-Ural State Medical University, Head Physician of Chelyabinsk Regional Clinical Oncology Center.
E-mail: roc_chel@mail.ru. SPIN-code: 1350-9411.
Е. B. Vasilyeva
Chelyabinsk Regional Oncology Center, Chelyabinsk
Russian Federation
Russian Federation
Vasilyeva Ekaterina Borisovna, MD, PhD, Head of Radiation Therapy Department.
E-mail: v_kat@rambler.ru.N. G. Afanasyeva
Chelyabinsk Regional Oncology Center, Chelyabinsk
Russian Federation
Russian Federation
Afanasyeva Nadezhda Gennadievna, MD, PhD, Head ofPositronEmissionTomographyCenter.
E-mail: afanas_ng@mail.ru.References
1. Kaprin A.D., Starinskij V.V., Petrova G.V. Cancer incidence in Russia in 2012 (morbidity and mortality). Moscow, 2014. 250 p. [in Russian]
2. Casara D., Rubello D., Saladini G., Masarotto G., Favero A., Girelli M.E., Busnardo B. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate analysis of prognostic variables // J. Nucl. Med. 1993. Vol. 34 (11). P. 1626–1631.
3. Davies L., Welch H.G. Increasing Incidence of Thyroid Cancer in the United States, 1973-2002 // JAMA. 2006. Vol. 295 (18). P. 2164–2167.
4. Dinneen S.F., Valimaki M.J., Bergstralh E.J., Goellner J.R., Gorman C.A., Hay I.D. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades // J. Clin. Endocrinol. Metabol. 1995. Vol. 80 (7). P. 2041–2045.
5. Durante C., Haddy N., Baudin E., Leboulleux S., Hartl D., Travagli J.P., Caillou B., Ricard M., Lumbroso J.D., De Vathaire F., Schlumberger M. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy // J. Clin. Endocrinol. Metabol. 2006. Vol. 91 (8). P. 2892–2289.
6. Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R., Pereira A.M., Romijn J.A., Smit J.W. Survival and death causes in differentiated thyroid carcinoma // J. Clin. Endocrinol. Metabol. 2006. Vol. 91 (1). P. 313–319.
7. Hooft L., Hoekstra O.S., Devillé W., Lips P., Teule G.J., Boers M., van Tulder M.W. Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer // J. Clin. Endocrinol. Metabol. 2001. Vol. 86 (8). P. 3779–3786.
8. Khan N., Oriuchi N., Higuchi T., Zhang H., Endo K. PET in the follow-up of differentiated thyroid cancer // Br. J. Radiol. 2003. Vol. 76 (10). P. 690–695.
9. O’Neill C.J., Oucharek J., Learoyd D., Sidhu S.B. Standard and emerging therapies for metastatic differentiated thyroid cancer // Oncologist. 2010. Vol. 15 (2). P. 146–156. doi: 10.1634/theoncologist.2009- 0190.
10. Schlumberger M.J. Diagnostic follow-up of well-differentiated thyroid carcinoma: Historical perspective and current status // J. Endocrinol. Investig. 1999. Vol. 22 (11). Suppl. P. 3–7.
11. Schlumberger M.J., Arcangioli O., Piekarski J.D., Tubiana M., Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays // J. Nucl. Med. 1988. Vol. 29 (11). P. 1790–1794.
12. Sherman S.I. Thyroid carcinoma // Lancet. 2003. Vol. 361 (9356). P. 501–511.
13. Sipos J.A., Mazzaferri E.L. Thyroid Cancer Epidemiology and Prognostic Variables // Clin. Oncol. (R. Coll. Radiol.). 2010. Vol. 22 (6). P. 395–404. doi: 10.1016/j.clon.2010.05.004.
14. Sisson J.C., Ackerman R.J., Meyer M.A., Wahl R.L. Uptake of 18- fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy // J. Clin. Endocrinol. Metabol. 1993. Vol. 77 (4). P. 1090–1094.
15. Wang H., Fu H.L., Li J.N., Zhou R.J., Hui G.Z, Wu J.C., Huang G. Comparison of whole-body 18F-FDG SPECT and posttherapeutic 131I scintigraphy in the detection of metastatic thyroid cancer // Clin. Imaging. 2008. Vol. 32 (1). P. 32–37. doi: 10.1016/j.clinimag.2007.07.010.
Review
For citations:
Geliashvili Т.М., Vazhenin A.V., Vasilyeva Е.B., Afanasyeva N.G. DIAGNOSTIC IMAGING MODALITIES FOR DETECTION OF LUNG METASTASES IN PATIENTS WITH DIFFRENTIATED THYROID CANCER. Siberian journal of oncology. 2015;(6):57-60. (In Russ.)
Views:
724
Email this article 
